(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -51.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.4%.
Arvinas's revenue in 2026 is $316,700,000.On average, 17 Wall Street analysts forecast ARVN's revenue for 2026 to be $18,893,339,889, with the lowest ARVN revenue forecast at $16,999,755,798, and the highest ARVN revenue forecast at $21,969,760,176. On average, 17 Wall Street analysts forecast ARVN's revenue for 2027 to be $3,936,902,560, with the lowest ARVN revenue forecast at $147,380,475, and the highest ARVN revenue forecast at $8,630,323,350.
In 2028, ARVN is forecast to generate $5,555,864,649 in revenue, with the lowest revenue forecast at $704,863,139 and the highest revenue forecast at $13,546,057,189.